AstraZeneca's shares experienced a significant decline of 8.9% on Monday, 3 August 2026, following reports of potential merger discussions with US pharmaceutical company Bristol Myers Squibb (BMS). The reported mega-merger is valued at $400bn (£300bn).
The Anglo-Swedish drugmaker has not yet released a statement to confirm the accuracy of the initial reports regarding these talks. Sir Pascal Soriot, AstraZeneca's chief executive, has previously overseen the company's acquisition of Alexion for $39bn (£29bn) in 2021, which expanded its presence in rare disease medicines.
Analysts have questioned the strategic rationale for AstraZeneca pursuing such a large acquisition, particularly given BMS's impending patent cliff challenge with its Opdivo cancer treatment, which is expected to see sales decline by 2030. US competition regulators may also scrutinise a merger that would combine two major oncology franchises.
Last autumn, AstraZeneca harmonised its listing on the New York Stock Exchange, giving it equal status with its London and Stockholm listings. CEO Sir Pascal Soriot recently expressed confidence in AstraZeneca hitting its 2030 target for annual revenues of $80bn.